Allison Lawton, SVP, Genzyme, on the major drivers of transparency in the pharmaceutical industry

in MediaWatch, Video
February 23rd, 2010

Allison Lawton, Senior Vice President of Regulatory Affairs at Public Policy at Genzyme Corporation,  reviews the importance of drug safety concerns as a catalyst for transparency in biopharma.

She then gives a glimpse, from the perspective of someone within the pharmaceutical industry,  into the challenges of meeting the public demand for increased—yet objective and useful—information.  Lawton also discusses the changes future leaders in the health and medical sectors will have to make to both meet the challenges, and reap the benefits, of greater transparency.

This text will be replaced

Related videos: